FDA panel backs Heplisav-B, wants rigorous postmarketing study

Dynavax Technologies Corp. (NASDAQ:DVAX) jumped $7.45 (81%) to $16.70 in after-hours trading on Friday after FDA's Vaccines and Related Biological Products Advisory Committee voted 12 to one, with three abstentions, that available safety data support the

Read the full 369 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE